Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Colorectal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm
Large Intestinal Neoplasm
Colorectal Neoplasm

Subtype

Colorectal Neoplasm

CI-CAN-00002404Explore in graph →

Non-malignant1,784 active trials21 approved drugs382 evidence items

NCIt: C2956
MeSH: D015179

Overview
Statistics
Survival
Genomics27
Variants & evidence382
Drugs79
Trials8604
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (357)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 251–275 of 357 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.
· Clin Cancer Res · 2012 · PMID 22357840 · validated civic_curation pubmed
Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.
· BMC Cancer · 2015 · PMID 26508446 · validated civic_curation pubmed
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
· Mol Clin Oncol · 2015 · PMID 26623049 · validated civic_curation pubmed
A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.
· Int J Cancer · 2016 · PMID 26152787 · validated civic_curation pubmed
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
· Int J Clin Exp Pathol · 2015 · PMID 25973082 · validated civic_curation pubmed
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.
· Med Oncol · 2013 · PMID 23579861 · validated civic_curation pubmed
Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.
· Gastroenterology · 2014 · PMID 24512910

Showing 251–275 of 357 publications

← Previous
1
…
10
11
12
…
15
Next →

· validated civic_curation

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

· J Clin Oncol · 2015 · PMID 26392102 · validated civic_curation pubmed

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.

· Br J Cancer · 2013 · PMID 23348520 · validated civic_curation pubmed

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

· J Clin Oncol · 2007 · PMID 17470858 · validated civic_curation pubmed

Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.

· Sci Rep · 2015 · PMID 26621817 · validated civic_curation pubmed

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.

· Nat Commun · 2016 · PMID 27302369 · validated civic_curation pubmed

Regorafenib in metastatic colorectal cancer.

· Expert Rev Anticancer Ther · 2014 · PMID 24559322 · validated civic_curation pubmed

Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.

· Scand J Gastroenterol · 2014 · PMID 24256029 · validated civic_curation pubmed

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

· Ann Oncol · 2013 · PMID 24146218 · validated civic_curation pubmed

Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer.

· J Cancer Res Clin Oncol · 2016 · PMID 27177629 · validated civic_curation pubmed

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.

· Cancer Chemother Pharmacol · 2015 · PMID 25322874 · validated civic_curation pubmed

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

· J Clin Oncol · 2004 · PMID 14993230 · validated civic_curation pubmed

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

· Ann Oncol · 2019 · PMID 31038663 · validated civic_curation pubmed

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

· Nature · 2012 · PMID 22722830 · validated civic_curation pubmed

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

· Nat Med · 2012 · PMID 22270724 · validated civic_curation pubmed

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.

· Clin Cancer Res · 2016 · PMID 26888827 · validated civic_curation pubmed

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

· Cancer Discov · 2016 · PMID 27325282 · validated civic_curation pubmed

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

· Cancer Discov · 2016 · PMID 26546295 · validated civic_curation pubmed

PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.

· Clin Cancer Res · 2017 · PMID 28424201 · validated civic_curation pubmed